What is the clinical significance of epidermal growth factor receptor (EGFR) mutations in advanced non‑squamous non‑small cell lung cancer?

Clinical Significance of EGFR Mutations in Advanced Non-Squamous NSCLC

EGFR mutations are the most critical predictive biomarker in advanced non-squamous NSCLC, mandating immediate molecular testing to guide first-line targeted therapy with EGFR tyrosine kinase inhibitors, which dramatically improve progression-free survival and quality of life compared to chemotherapy. 1

Prevalence and Mutation Types

EGFR alterations occur in approximately 10% of white patients, 19% of Black patients, and up to 50% of Asian patients with NSCLC 1. The two most common mutations—exon 19 deletions (with conserved LREA deletion) and exon 21 L858R point mutation—represent 85-90% of all EGFR alterations and both activate the tyrosine kinase domain, conferring sensitivity to EGFR TKIs 1.

Less common mutations (approximately 10%) include:

• Exon 20 S768I
• Exon 21 L861Q
• Exon 18 G719X

These uncommon mutations show varying sensitivity to different generations of EGFR TKIs 1.

Predictive Value for Treatment Response

Common Mutations (Exon 19 Deletions and L858R)

For patients with exon 19 deletions or L858R mutations, EGFR TKIs should be used as first-line therapy instead of chemotherapy 1. The predictive effects are well-established:

• Objective response rates: 55-80% with EGFR TKIs 1
• Median PFS: 9.2-13 months with first-generation TKIs 1
• Median PFS: 18.9 months with osimertinib versus 10.2 months with erlotinib/gefitinib 1
• Median OS: 38.6 months with osimertinib versus 31.8 months with first-generation TKIs 1

Importantly, patients receiving EGFR TKIs experience fewer severe treatment-related side effects and improved quality of life compared to chemotherapy, with decreased cough, dyspnea, and better health-related quality of life 1.

Uncommon Mutations (S768I, L861Q, G719X)

The NCCN recommends afatinib or osimertinib as preferred first-line therapy for patients with EGFR S768I, L861Q, and/or G719X mutations 1. Response rates vary by specific mutation:

With afatinib:

• S768I: 100% response rate 1
• G719X: 77.8% response rate 1
• L861Q: 56.3% response rate 1

With osimertinib:

• L861Q: 78% response rate, median PFS 15.2 months 1
• G719X: 53% response rate, median PFS 8.2 months 1
• S768I: 38% response rate, median PFS 12.3 months 1

Retrospective data suggest NSCLC with L861Q may respond better to osimertinib than afatinib 1.

Testing Methodology

DNA mutational analysis is the preferred method to assess EGFR status 1. Direct sequencing of exons 18-21 (or just exons 19 and 21) is reasonable, but more sensitive methods are available 1. Multiplex PCR assays and next-generation sequencing can detect EGFR mutations with higher sensitivity 1.

EGFR mutation testing is not usually recommended in pure squamous cell carcinoma unless the patient never smoked, only a small biopsy was obtained, or histology is mixed 1. EGFR mutations can occur in adenosquamous carcinoma, which is harder to discriminate from squamous cell in small specimens 1.

Resistance Mechanisms

EGFR T790M is an exon 20 mutation associated with acquired resistance, occurring in approximately 60% of patients with disease progression after initial response to first- or second-generation EGFR TKIs 1. Most patients with sensitizing EGFR mutations develop resistance after approximately 9-13 months of EGFR TKI therapy 1.

For patients who develop T790M-mediated resistance, osimertinib is recommended (category 1) as subsequent therapy 1. If T790M is identified in the absence of prior EGFR TKI therapy, genetic counseling and possible germline genetic testing are warranted, as germline EGFR T790M confers high risk for lung cancer regardless of smoking status 1.

Clinical Implications Beyond Treatment Selection

EGFR mutations are associated with specific clinical characteristics:

• More common in females than males (47% vs 12%) 2
• More common in younger patients (38% vs 10% in older patients) 2
• More common in nonsmokers (47% vs 13% in smokers) 2
• More common in well-differentiated tumors (39% vs 7% in poorly differentiated) 2

Patients with EGFR mutations show longer local control after definitive chemoradiotherapy (adjusted HR 0.49), suggesting radiosensitive biology of EGFR-mutated tumors 3.

Critical Pitfalls to Avoid

Do not use immune checkpoint inhibitors as monotherapy before exhausting standard therapeutic options in EGFR-mutant NSCLC, regardless of PD-L1 expression 1. ICIs show limited efficacy in EGFR-mutant disease and increase risk of toxicity with subsequent TKI treatment, including potentially severe pneumonitis 1.

Do not add EGFR TKIs to concurrent chemotherapy based on CALGB 30406 data showing erlotinib alone was associated with fewer side effects than erlotinib/chemotherapy combinations 1. If sensitizing EGFR mutations are discovered during chemotherapy, it is appropriate to interrupt or complete planned chemotherapy and switch to EGFR TKI monotherapy 1.

Obtain repeat biopsy and/or liquid biopsy at progression to identify specific resistance mechanisms, as this may guide subsequent treatment selection 1, 4.